Abacavir - Innovation Pharmaceuticals

Drug Profile

Abacavir - Innovation Pharmaceuticals

Alternative Names: abacavir acetate - Innovation Pharmaceuticals; KM-133; Prurisol

Latest Information Update: 15 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer Innovation Pharmaceuticals
  • Class Antipsoriatics; Antiretrovirals; Cyclopentanes; Cyclopropanes; Dideoxynucleosides; Small molecules
  • Mechanism of Action HIV replication inhibitors; Immunomodulators; Nucleoside reverse transcriptase inhibitors; PRINS expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Psoriasis

Highest Development Phases

  • Phase II Plaque psoriasis

Most Recent Events

  • 15 Oct 2018 Abacavir is still in phase II development for Plaque psoriasis in USA (Innovation Pharmaceuticals pipeline, October 2018)
  • 31 Dec 2017 Innovation Pharmaceuticals completes a phase IIb trial in Plaque psoriasis in USA (NCT02949388)
  • 30 Nov 2017 Innovation Pharmaceuticals completes enrolment in a phase IIb trial in Plaque psoriasis in USA (NCT02949388)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top